Narikazu Boku

22PUBLICATIONS
102CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedCancer geneticsMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 16, 2026
A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).

|Sep 05, 2026
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

|Jan 08, 2026
Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database.

Gota Fujisawa, Kenji Tamada, Takeshi Hayashi

|May 23, 2025
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata

Pageof 4

Frequent Collaborators

4 joint publications

Hisato Kawakami

4 joint publications

Shigenori Kadowaki

3 joint publications

Takeru Wakatsuki

3 joint publications

Hirokazu Shoji